Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

J&J's plan is to have a specially created subsidiary, Red River Talc, go into Chapter 11 bankruptcy and have claims paid out through it. AbbVie, Teva, Cigna Thermo Fisher in focus after quarterly ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...

AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development ...

Apheris’ consortium of pharma companies is partnering with OpenFold3 — Columbia professor Mohammed AlQuraishi’s open-source dupe of AlphaFold3 — to train the model on AbbVie and Johnson ...